Format

Send to

Choose Destination
See comment in PubMed Commons below
J Drugs Dermatol. 2013 Mar;12(3):317-20.

The efficacy of ustekinumab in psoriasis.

Author information

1
Universidad Nacional de Córdoba, Córdoba, Argentina.

Abstract

Psoriasis is an immune-mediated cutaneous disease affecting 2% of the worldwide population. While topical therapy, phototherapy, oral systemic therapy, and biologic agents have been used, the treatment of psoriasis still remains a challenge. Ustekinumab is a biologic therapy that provides a novel avenue for management by blocking interleukin-12/23. The purpose of this article is to review the mechanism of action of ustekinumab and its efficacy in psoriatic patients. The use of ustekinumab in other immune-mediated diseases is also discussed. It is our goal to provide dermatologists with the knowledge to enable them to incorporate ustekinumab into their practice.

PMID:
23545915
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for SanovaWorks
    Loading ...
    Support Center